Login to Your Account

Marketing Applications in Early 2013

The Next Big ERT? BioMarin Jumps on Solid GALNS Data

By Jennifer Boggs
Managing Editor

Tuesday, November 6, 2012
Hailed as a key growth driver for BioMarin Pharmaceuticals Inc., GALNS (N-acetylgalactosamine-6 sulfatase) came through with solid Phase III data in rare lysosomal storage disorder mucopolysaccharidosis Type IVA (MPS IVA), sending shares of the Novato, Calif.-based biotech soaring 31.2 percent Monday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription